Pregled bibliografske jedinice broj: 1174737
Stable gastric pentadecapeptide BPC 157 may counteract myocardial infarction induced by isoprenaline in rats
Stable gastric pentadecapeptide BPC 157 may counteract myocardial infarction induced by isoprenaline in rats // Biomedicines, 10 (2022), 2; 265, 38 doi:10.3390/biomedicines10020265 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1174737 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Stable gastric pentadecapeptide BPC 157 may counteract myocardial infarction induced by isoprenaline in rats
Autori
Barišić, Ivan ; Balenović, Diana ; Udovičić, Mario ; Bardak, Darija ; Strinić, Dean ; Vlainić, Josipa ; Vraneš, Hrvoje ; Smoday, Ivan M. ; Krezić, Ivan ; Milavić, Marija ; Sikirić, Sunčana ; Uzun, Sandra ; Živanović Posilović, Gordana ; Štrbe, Sanja ; Vukoja, Ivan ; Lovrić, Eva ; Lozić, Marin ; Sever, Marko ; Lovrić Benčić, Martina ; Boban Blagaić, Alenka ; Skrtić, Anita ; Seiwerth, Sven ; Sikirić, Predrag
Izvornik
Biomedicines (2227-9059) 10
(2022), 2;
265, 38
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
pentadecapeptide BPC 157 ; isoprenaline ; occlusion-like syndrome ; myocardial infarction ; oxidative stress ; L-NAME ; L-arginine ; rats
Sažetak
We revealed that the stable gastric pentadecapeptide BPC 157, a useful peptide therapy against isoprenaline myocardial infarction, as well as against isoprenaline myocardial reinfarction, may follow the counteraction of the recently described occlusion-like syndrome, induced peripherally and centrally, which was described for the first time in isoprenaline- treated rats. BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.). At 30 min after isoprenaline 75 mg/kg s.c., we noted an early multiorgan failure (brain, heart, lung, liver, kidney and gastrointestinal lesions), thrombosis, intracranial (superior sagittal sinus) hypertension, portal and caval hypertension, and aortal hypotension, in its full presentation (or attenuated by BPC 157 therapy (given at 5 min after isoprenaline) via activation of the azygos vein). Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period). BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT, and attenuated gross (no visible infarcted area) and histological damage, ECG (no ST-T ischemic changes), and echocardiography (preservation of systolic left ventricular function) damage induced by isoprenaline. Its effect was associated with a significant decrease in oxidative stress parameters and likely maintained NO system function, providing that BPC 157 interacted with eNOS and COX2 gene expression in a particular way and counteracted the noxious effect of the NOS- blocker, L-NAME.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Medicinski fakultet, Osijek
Profili:
Marin Lozić (autor)
Ivan Barišić (autor)
Dean Strinić (autor)
Predrag Sikirić (autor)
Anita Škrtić (autor)
Sanja Štrbe (autor)
Sunčana Sikirić (autor)
Sven Seiwerth (autor)
Martina Lovrić Benčić (autor)
Ivan Krezić (autor)
Marija Milavić (autor)
Alenka Boban Blagaić (autor)
Marko Sever (autor)
Eva Lovrić (autor)
Ivan Vukoja (autor)
Josipa Vlainić (autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus